The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 11, 2024

Filed:

Apr. 12, 2021
Applicant:

University of Maryland, Baltimore, Baltimore, MD (US);

Inventors:

Eduardo Davila, Cockeyville, MD (US);

Koji Tamada, Ube, JP;

Assignee:

UNIVERSITY OF MARYLAND, Baltimore, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 35/17 (2015.01); A61K 39/395 (2006.01); A61K 47/54 (2017.01); A61K 47/68 (2017.01); C07K 16/28 (2006.01); C07K 16/44 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); A61K 35/17 (2013.01); A61K 39/39558 (2013.01); A61K 47/555 (2017.08); A61K 47/6855 (2017.08); A61K 47/6859 (2017.08); A61K 47/6863 (2017.08); A61K 47/6897 (2017.08); C07K 16/2863 (2013.01); C07K 16/44 (2013.01); C12N 5/0636 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/572 (2013.01); A61K 2039/585 (2013.01); C07K 2317/622 (2013.01); C07K 2319/00 (2013.01); C12N 2501/515 (2013.01); C12N 2510/00 (2013.01);
Abstract

The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, αFITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of αFITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer.


Find Patent Forward Citations

Loading…